Dermata Therapeutics, Inc.
DRMAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. At a $6.0M market cap, Dermata Therapeutics, Inc. ranks as a micro-cap company within healthcare. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand.
Market Cap
$6.0M
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
-0.31
EPS (TTM)
$-4.07
EPS (Fwd)
$-3.87
ROE
-183.9%
ROA
-89.9%
Cash
$4.4M
Total Debt
$0
Free CF
-$5.1M
52W Change
-76.6%
Annual Financials
Cash vs Debt
Where DRMA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, DRMA finished 3.76% below its 150-day moving average ($1.33) and 20.99% below its 200-day moving average ($1.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DRMA overbought or oversold?
At the September 3, 2026 close, DRMA's RSI(14) was 36.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Dermata Therapeutics, Inc. reports $4.4M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$5.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -183.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Dermata Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DRMA.